Evaluation of serum activity of aspartate transaminase, alanine transaminase and alkaline phosphatases in Sudanese with long standing type 2 diabetes mellitus

Murga Sulafa; Eltom Abdelgadir; L Osman Ahmed

doi:10.30574/gscbps.2020.12.1.0212

Authors

Murga Sulafa University of Sciences &Technology, Faculty of Medical Laboratory Sciences, Department of Clinical Chemistry, Omdurman, Sudan.
Eltom Abdelgadir Medical Laboratories Sciences, College of Health Sciences, Gulf Medical University, Ajman, UAE.
L Osman Ahmed Medical Laboratories Sciences, College of Health Sciences, Gulf Medical University, Ajman, UAE.

DOI:

https://doi.org/10.30574/gscbps.2020.12.1.0212

Keywords:

Type2 diabetes mellitus, Alanine aminotransferase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Sudan

Abstract

Background Diabetes, the most common non- communicable disease in Sudan, is having an increasing impact or rates of morbidity and mortality. The spread of sedentary lifestyle and adoption of western dietary habits-high in refine carbohydrates and fat- are driving an increase in the number of people with obesity related type 2 diabetes. The study aims to evaluate the plasma activities in enzymes (AST, ALT and ALP) in Sudanese with long standing diabetes mellitus type 2 compared with healthy subjects (non diabetics) as a control group. Method a cross-sectional study conducted during the period from April to September 2009, compared plasma activities of Aspartate, Alanine Transaminases and Alkaline Phosphatase of 40 Sudanese patients with type 2 diabetes mellitus (as a test group), and 30 apparently healthy volunteers (as a control group). Participants in this study were from Bahri Diabetic Centre in Sudan. Age and gender of test group were matched with control group. The plasma activities of AST, ALT and ALP were measured using A 25 auto analyzer from Roche/ Hitachi Company, Germany. Results in this study forty patients with diabetes mellitus type 2, in addition to 30 healthy volunteers as a control group were enrolled in this study. Age and gender of the test group were matched with the control group Plasma AST, ALT showed insignificant difference, whereas plasma ALP was significantly raised in the test group compared to the control group: (61.08 ± 19.625) versus (57.23 ± 14.616) U/L (P= 0.415); for plasma AST. (64.15 ± 18.972) versus (62.07 ± 14.605) U/L (P= 0.825); for plasma ALT. (278.73± 88.963) versus (161.50 ± 81.708) U/L (P= 0.000); for plasma ALP. In the test group, both plasma AST and ALT showed no correlation with the duration of the disease, while plasma ALP showed a weak positive correlation with the duration of diabetes mellitus. Conclusions in this study we found that Sudanese patients with type2 diabetes mellitus have a high incidence of abnormal ALP levels. Timely diagnosis and management of the abnormal liver parameters may help to minimize liver-related morbidity and mortality in the diabetic population.

Metrics

Metrics Loading ...

References

Bishop ML, Edward PF and Larry S. (2017). Carbohyderates.Clinical Chemistry; Principles, procedures, correlations 8th ed. Lipincott & Wilkin; Philadelphia,. PP 743-765.

American Diabetes Association. (2011). Diagnosis and classification of diabetes mellitus. Diabetes Care, 34 Suppl 1(Suppl 1), 62-69.

National Diabetes Data Group. (1979). Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039-57.

D Wooton. (1982). Microanalysis in medical biochemistry, London, sixth edition ch, 8, 250-260.

Agus S and Cox R. (1966). Griffin, M. Inhibition of Alkaline phosphatase by cysteine and it is Analogues, Biochim Biophys Acta, 118-363.

Burtis CA and Ashwood ER. (1999). Teitz text book of clinical chemistry .3rd edition, WBSaunders co, 501-613.

Low MG and Zilversmit DB. (2006). Alkaline phosphatase and exchange surfaces. J Clin Chem.

American Diabetes Association. (2009).Total prevelance of diabetes and pre diabetes. retrieves on; Marach. USA, 3-17.

Narayan K, Boyle J, Tompson T, Sorensen S and Williamson D. (2003). life time risk for diabetes mellitus in the united states 2 JAMA, (14).

Mekenzie J. (2006). Plasma liver enzymes source. Clinical endocrinology , 35 (5), 40-44.

Y. Li, Jing wang and Xu.Han. (2019). / Annals of Hepatology, 18, 298–303.

Fraser A, et al. (2009). Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care, 32, 741–750.

Hanley AJ, et al. (2004). Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 53, 2623–2632.

Andre P, et al. (2005). Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study - The DESIR study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes & Metabolism, 31, 542–550,

Schneider ALC, et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetic Med, 30, 926–933.

Sattar N et al. (2004). Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes, 53, 2855–2860.

Ozarova B et al. (2002). High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes, 51, 1889–1895.

Siddiqi SS, Borse AG, Pervez A and Anjum S. (2017). A study of bone turnover markers in gestational diabetes mellitus. Indian journal of endocrinology and metabolism, 21(1), 38.

Chen SC, Tsai SP, Jhao JY, Jiang WK, Tsao CK and Chang LY. (2017). Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes: a prospective study of 132,377 adults. Scientific reports, 5, 7(1), 1-9.

Perry IJ, Wannamethee SG and Shaper AG. (2019). Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care, 21, 732–737.

Nannipieri M, et al. (2005). Liver enzymes, the metabolic syndrome, and incident diabetes: The Mexico City Diabetes Study. Diabetes Care, 28, 1757–1762.

Cheung CL, Tan KC, Lam KS and Cheung BM. (2013). The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: a structural equation modeling approach. The Journal of Clinical Endocrinology & Metabolism, 1, 98(9), 3856-63.